Zepbound

What is Zepbound?

Zepbound is Eli Lilly’s once-weekly tirzepatide injection for chronic weight management. The FDA approved it in November 2023, and added moderate to severe obstructive sleep apnea in adults with obesity in December 2024.

It is the same molecule as Mounjaro, sold under a different name with a different set of approvals. It is not the same drug as Ozempic or Wegovy: those are semaglutide, and tirzepatide is a different molecule that acts on two receptors instead of one.

It comes as a single-dose pen, a KwikPen, and a single-dose vial. Which one you have matters more than it sounds: their storage windows differ, and Medicare’s temporary GLP-1 Bridge covers the KwikPen only.

Who is Zepbound approved for?

Adults with obesity, or adults with overweight plus at least one weight-related condition. The indication does not name a BMI number. The familiar thresholds of 30, or 27 with a related condition, describe who was enrolled in the trials rather than what the label says, which is worth knowing when an insurer quotes them as an FDA rule.

The sleep-apnea indication is narrower: moderate to severe obstructive sleep apnea in adults with obesity. It is not a general treatment for sleep apnea. Unlike Wegovy and Saxenda, Zepbound has no pediatric indication. The label also advises against taking it alongside another tirzepatide product or any other GLP-1 medicine.

How much weight can you lose on Zepbound?

In the pivotal 72-week trial in adults with obesity or overweight and without type 2 diabetes, weight fell 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg, against 3.1 percent on placebo. Subtracting placebo, that is 11.9, 16.4 and 17.8 percentage points. More than 90 percent of people on 15 mg lost at least 5 percent of their body weight, and 83.5 percent lost at least 10 percent.

The companion trial in people who also had type 2 diabetes produced smaller numbers on the same doses: 12.8 percent at 10 mg and 14.7 percent at 15 mg, against 3.2 percent on placebo.

Those are the largest average weight reductions of any approved medication. Two honest caveats belong right next to that fact. Cross-drug comparisons are mostly indirect, so “largest in class” rests on comparing separate trials rather than on head-to-head evidence, with one exception covered below. And the biggest number on the scale is not the same as the best-proven outcomes: Zepbound carries no cardiovascular outcomes indication, while Wegovy does. That trade-off is the real comparative story, and it rarely gets told.

No trial figure is the drug on its own, either. Every arm in these programs received structured lifestyle support, and the drug effect was measured on top of it. Results varied widely between individuals.

How does Zepbound work?

Tirzepatide acts on the receptors for two gut hormones, GIP and GLP-1, while semaglutide acts on GLP-1 alone. It is a genuinely different drug rather than a stronger dose of the same one, and what GIP adds on its own is not fully settled.

GLP-1 is a hormone your gut already releases when you eat. Activating its receptor reduces appetite, acting on the parts of the brain that handle hunger and food reward, and the weight loss comes mainly from eating less rather than from burning more.

It also slows how quickly the stomach empties. That adds to fullness, and it is where most of the nausea comes from. The effect tends to fade as your body adjusts, and many people lose weight without ever feeling sick.

That same slowdown has one consequence people are rarely warned about: it can reduce how well an oral contraceptive is absorbed. The label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Non-oral hormonal methods are not affected.

Zepbound for sleep apnea

The sleep-apnea approval is a real second indication, built on dedicated trials rather than extrapolated from weight loss.

In those trials Zepbound reduced the apnea-hypopnea index, the count of breathing interruptions per hour of sleep, by about 20 to 24 events per hour more than placebo. Between 42 and 50 percent of participants reached remission or mild, non-symptomatic disease. The effect was driven mainly by the accompanying weight loss of roughly 16 to 17 percent.

Three things to hold alongside that. The apnea-hypopnea index is a surrogate measure with well-described limits, and no cardiovascular or mortality outcomes were measured. Participants were close to symptom-free at baseline, so the evidence for feeling less sleepy during the day is weak. And the trials ran both with and without PAP therapy: this was studied as an addition to care, not a replacement, and the label does not authorize stopping PAP.

For this indication the label names only the 10 mg and 15 mg doses. The 5 mg weight-management maintenance dose is not a sleep-apnea dose.

What are the side effects of Zepbound?

Mostly digestive, mostly early, and mostly clustered around dose increases. Each rate below comes from the placebo-controlled trials and is shown against the placebo rate in the same trials, because the raw figure alone overstates what the drug adds.

A note on injection-site reactions, because the number in circulation is often the wrong one. In the placebo-controlled trials they occurred in 6 to 8 percent of people on Zepbound against 2 percent on placebo. A separate analysis looked only at people who developed anti-drug antibodies and found 11.3 percent, against 1 percent in those who did not. That second figure has no placebo group and is not the general rate.

Antibodies to tirzepatide are common, in about 64 percent of people in the weight trials. The label reports no identified clinically significant effect on how the drug behaves in the body or on how well it works. Separately, people who developed antibodies had more hypersensitivity and injection-site reactions. Those are two different findings and both belong in the picture. Antibody rates also cannot be compared across drugs, because the assays differ and the labels say so.

On the eyes, the tirzepatide labels differ from semaglutide’s in a way worth stating precisely. Semaglutide’s label carries a retinopathy finding with numbers behind it. Tirzepatide’s says the drug has not been studied in proliferative retinopathy, retinopathy needing acute treatment, or macular edema, and advises monitoring people with a history of retinopathy. That is an absence of data rather than a signal.

Because the drug slows stomach emptying, the label instructs patients to tell their care team before any procedure requiring general anesthesia or deep sedation. The suicidality warning that drove headlines in 2023 and 2024 was removed from the Zepbound label in February 2026, after FDA reviewed the question and did not find an increased risk. Ordinary vigilance still applies: tell your prescriber about new or worsening depression or mood changes.

Practical management, which rests on clinical experience rather than trials of the advice itself: smaller meals, less fatty food and alcohol around injection day, and enough fluid. Persistent severe abdominal pain is not a symptom to wait out.

Who should not take Zepbound?

The label lists exactly two contraindications. The rest are worth raising with your prescriber before you start.

The boxed warning drives the first: because tirzepatide caused thyroid C-cell tumors in rats, anyone with a personal or family history of medullary thyroid cancer, or with MEN 2, should not take it. The second is a serious hypersensitivity reaction to tirzepatide or any ingredient.

Zepbound dosage: schedule and strengths

Everyone starts at 2.5 mg once weekly for four weeks, then steps up in 2.5 mg increments after at least four weeks at each dose. The label is explicit that 2.5 mg is for treatment initiation and is not approved as a maintenance dosage.

The maintenance doses are 5, 10, or 15 mg for weight management, and 10 or 15 mg for sleep apnea. The maximum is 15 mg. Which one you settle on is explicitly a judgment call: the label says to consider response and tolerability, and the trials were not designed to compare maintenance doses against each other.

Missed a dose? Zepbound’s label says to take it as soon as possible within 4 days (96 hours). That window is specific to tirzepatide and does not transfer: Ozempic’s label says 5 days, and the daily tablets say to skip the dose entirely.

How do you use the Zepbound pen?

Zepbound comes in three presentations that do not operate identically. The steps below are a summary. Follow the Instructions for Use for your exact product, and ask your pharmacist or prescriber to walk you through it the first time.

1. Check the medicine and the device as your Instructions for Use direct.
2. Inject under the skin of the abdomen or thigh. These are the two sites you use on yourself.
3. The upper arm is different on tirzepatide. Both the Zepbound and Mounjaro labels direct that another person give the injection in the back of the upper arm. This is not true of every GLP-1, and it is the most commonly repeated error about this drug.
4. Use a different spot within the area each week. The label instructs rotation and gives no reason for it.
5. Dispose of needles in a sharps container, and never share a KwikPen with another person even with a new needle.

Storage depends on the presentation, and the windows really are different. Single-dose pens and single-dose vials are refrigerated, and may be kept unrefrigerated up to 86°F for a total of 21 days. The KwikPen and multi-dose vial get 30 days.

How much does Zepbound cost?

List price is not what most people pay, and Lilly cut its self-pay prices in December 2025. The figures below move often, so confirm them before acting.

Coverage for obesity treatment is a patchwork. Roughly a third of the largest employers cover it, far fewer state Medicaid programs do, and where coverage exists it often carries prior authorization, BMI rules, step therapy, or a lifestyle-program requirement.

Medicare has one narrow, temporary route with a detail specific to this drug. The GLP-1 Bridge runs from 1 July 2026 through the end of 2027 at $50 a month for people who meet its criteria, and for Zepbound it covers the KwikPen only. The single-dose pen and single-dose vial are not included, and pen needles are not covered.

Zepbound vs Wegovy, Mounjaro, and Ozempic

Zepbound vs Wegovy

The one place a direct comparison exists. Over 72 weeks, tirzepatide produced 20.2 percent weight loss against semaglutide’s 13.7 percent, and more people reached a 25 percent loss. It was an open-label trial funded by Eli Lilly, comparing each drug at its maximum tolerated dose. Tolerability did not come out worse: discontinuations for digestive side effects were lower on tirzepatide than on semaglutide in that trial. The counterweight is the indication gap. Wegovy is approved to reduce major cardiovascular events and Zepbound is not, though Zepbound is approved for sleep apnea and Wegovy is not. Compare every GLP-1 →

Zepbound vs Mounjaro

Same molecule, different products. Mounjaro is approved for type 2 diabetes, in adults and in children 10 and older. Zepbound is approved for weight management and sleep apnea, in adults only. Compare every GLP-1 →

Zepbound vs Ozempic

Different molecules and different jobs. Ozempic is semaglutide, approved for type 2 diabetes and, in people who also qualify, for cardiovascular and kidney risk reduction. Weight comparisons between them are indirect, since the direct trial was against Wegovy. Compare every GLP-1 →

Looking beyond the brand? See every Zepbound alternative →

How to get Zepbound

Zepbound is prescription-only, and a licensed provider has to write it. Sites offering it without a prescription are not selling the approved product. Three legitimate paths:

Zepbound myths and misconceptions

Five claims we hear constantly, and what is actually true.

• Myth Zepbound is the same as Ozempic or Wegovy.

  It is not. Zepbound is tirzepatide, which acts on two gut-hormone receptors. Ozempic and Wegovy are semaglutide, which acts on one. Different molecule, different maker.

• Myth Zepbound is the same as Mounjaro.

  Here the answer is yes on the molecule. Both are tirzepatide from Eli Lilly. Mounjaro carries the type 2 diabetes approval; Zepbound carries the weight-management and sleep-apnea approvals.

• Myth Because it takes off the most weight, it is the best-proven option.

  Those are two different questions. Zepbound produced the largest weight loss of any approved drug, but it has no cardiovascular outcomes indication, and Wegovy does. Biggest effect on the scale is not the same as best-proven outcomes.

• Myth On Zepbound you will never need CPAP again.

  It was studied alongside PAP therapy rather than as a replacement, in people both on and off it, and the label does not authorize stopping. That is a decision for your sleep clinician.

• Myth Compounded tirzepatide is equivalent to Zepbound.

  Compounded versions are not FDA-approved products, and their dose and purity are not reviewed the way an approved product's are.